skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: A meta-analysis

Frontiers in endocrinology (Lausanne), 2023-02, Vol.14, p.1108234-1108234 [Peer Reviewed Journal]

Copyright © 2023 Yan, Ma, Yan and Han. ;Copyright © 2023 Yan, Ma, Yan and Han 2023 Yan, Ma, Yan and Han ;ISSN: 1664-2392 ;EISSN: 1664-2392 ;DOI: 10.3389/fendo.2023.1108234 ;PMID: 36926038

Full text available

Citations Cited by
  • Title:
    Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: A meta-analysis
  • Author: Yan, Bing ; Ma, Sicong ; Yan, Chenghui ; Han, Yaling
  • Subjects: Cardiovascular Diseases - complications ; coronary artery disease ; Coronary Artery Disease - complications ; Coronary Artery Disease - diagnosis ; death ; Endocrinology ; fibroblast growth factor (FGF 21) ; Fibroblast Growth Factors ; heart failure ; Heart Failure - complications ; Humans ; major adverse cardiac event (MACE) ; Prognosis
  • Is Part Of: Frontiers in endocrinology (Lausanne), 2023-02, Vol.14, p.1108234-1108234
  • Description: The role of fibroblast growth factor 21 (FGF21) in predicting the long-term prognosis of patients with cardiovascular disease (CVD) remains unknown. A comprehensive search in PubMed, Embase, and the Cochrane Library was performed to identify studies reporting the association between FGF21 and prognosis among patients with CVD. A meta-analysis was performed, with patients stratified by coronary artery disease (CAD) or heart failure (HF). The endpoint of CAD or HF was major adverse cardiovascular events defined by each study and a composite of death or HF readmission, respectively. The I method and linear regression test of funnel plot asymmetry were used to test heterogeneity (I > 50% indicates substantial heterogeneity) and publication bias (asymmetry P < 0.05, indicating publication bias). A total of 807 records were retrieved, and nine studies were finally included. Higher FGF21 levels were significantly associated with the risk of major adverse cardiovascular events in patients with CAD (multivariate hazard ratio [HR]: 1.77, 95% confidence interval [CI]: 1.40-2.23, P < 0.05, I = 0%, fixed-effect model). Increased FGF21 levels were also associated with the risk of all-cause death among patients with CAD (multivariate HR: 2.67, 95% CI: 1.25-5.72, P < 0.05, I = 64%, random-effect model). No association was found between FGF21 and the endpoint among patients with HF (HR: 1.57, 95% CI: 0.99-2.48, P > 0.05, random-effect model), but a large heterogeneity (I = 95%) and potential publication bias (Asymmetry P < 0.05) existed in the analysis. Increased FGF21 levels were independently associated with poor prognosis of CAD, whereas the role of FGF21 in predicting clinical outcomes of HF requires further investigation.
  • Publisher: Switzerland: Frontiers Media S.A
  • Language: English
  • Identifier: ISSN: 1664-2392
    EISSN: 1664-2392
    DOI: 10.3389/fendo.2023.1108234
    PMID: 36926038
  • Source: Freely Accessible Journals
    Open Access: PubMed Central
    MEDLINE
    ROAD: Directory of Open Access Scholarly Resources
    DOAJ Directory of Open Access Journals
Back to results list
Go to Previous pagePrevious Result  11 NextGo to Next page
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait